Sector revisions Genmab A/S

Equities

Real-time Estimate Cboe Europe Other stock markets 15:40:59 16/04/2026 BST			5-day change	1st Jan Change
1,793.25 ^DKK	-2.49%		-0.08%	-11.15%

04-15	Nordic Equities in North America - Astra Zeneca Gains 0.9 Percent	FW
04-14	Genmab A/S Provides Net Sales of Darzalex Results for the First Quarter of 2026	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
GENMAB A/S				14
ARGENX SE				15
WUXI APPTEC CO., LTD.				18
INSMED INCORPORATED				20
BIONTECH SE				18
WUXI BIOLOGICS (CAYMAN) INC.				21
AKESO, INC.				20
SUMMIT THERAPEUTICS INC.				14
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.				17
MADRIGAL PHARMACEUTICALS, INC.				14
EXELIXIS, INC.				18
REMEGEN CO., LTD.				15
ARROWHEAD PHARMACEUTICALS, INC.				11
SAMSUNG EPIS HOLDINGS CO., LTD.	-	-	-	1
VAXCYTE, INC.				9
NUVALENT, INC.				18
CYTOKINETICS, INCORPORATED				18
IMMUNITYBIO, INC.				5
PHARMAESSENTIA CORPORATION				7
Average				14
Weighted average by Cap.				16